Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
410 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06793215 | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer(Krascendo 2) | recruiting | Phase 3 | 600 | Hoffmann-La RocheINDUSTRY | 28 | Sep 8, 2026 | clinicaltrials |
| NCT01949129 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | recruiting | Phase 2 / Phase 3 | 1,800 | St. Anna Kinderkrebsforschung |
| 31 |
| Sep 4, 2026 |
| clinicaltrials |
| NCT06274515 | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies(REMERGE) | recruiting | Phase 4 | 320 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | recruiting | Phase 1 | 329 | Arvinas Inc.INDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT06713525 | Observational Copenhagen Pancreatic Cancer Study(COPAN) | recruiting | — | 8,000 | Inna Chen, MDOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07752992 | A Brief Psychological Intervention for Carer Fear of Cancer Progression | recruiting | N/A | 14 | University of AarhusOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05533775 | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma(iMATRIX GLO) | recruiting | Phase 1 / Phase 2 | 65 | Hoffmann-La RocheINDUSTRY | 13 | Sep 3, 2026 | clinicaltrials |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)(OMAHA-003) | recruiting | Phase 3 | 1,310 | Merck Sharp & Dohme LLCINDUSTRY | 36 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06343402 | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | recruiting | Phase 1 | 350 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 5 | Sep 3, 2026 | clinicaltrials |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer(ReDiscover-2) | recruiting | Phase 3 | 540 | Relay Therapeutics, Inc.INDUSTRY | 24 | Sep 3, 2026 | clinicaltrials |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer(DE-01) | recruiting | Phase 3 | 600 | AstraZenecaINDUSTRY | 23 | Sep 3, 2026 | clinicaltrials |
| NCT07803406 | Multimodal Imaging of Basal Cell Carcinoma: A Usability Study | recruiting | — | 50 | Bispebjerg HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04611867 | Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)(BetterEveryDay) | recruiting | N/A | 274 | Inna Chen, MDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | recruiting | Phase 3 | 448 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 18 | Sep 2, 2026 | clinicaltrials |
| NCT07780123 | Nurture by Nature Feasibility Study | recruiting | N/A | 127 | Ina Olmer SpechtOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06285318 | A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials(REALiTEC/TAL) | recruiting | — | 900 | Janssen-Cilag Ltd.INDUSTRY | 11 | Aug 28, 2026 | clinicaltrials |
| NCT06726148 | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Novartis PharmaceuticalsINDUSTRY | 16 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07791017 | Focused Ultrasound of the Popliteal Fossa for Detection of Symptomatic Baker's Cysts in Patients With Suspected Deep Vein Thrombosis: A Pilot Diagnostic Accuracy Study(BAKER-DVT) | recruiting | — | 150 | Aarhus University HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)(eVOLVECervical) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 19 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Aug 25, 2026 | clinicaltrials |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 130 | PedAL BCU, LLCOTHER | 20 | Aug 24, 2026 | clinicaltrials |
| NCT07237984 | Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway(COCO-S) | recruiting | — | 2,000 | Nordsjaellands HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06414954 | Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis(SYNAPSE-MG) | recruiting | Phase 2 | 84 | NMD Pharma A/SINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT07209111 | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014) | recruiting | Phase 2 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Aug 21, 2026 | clinicaltrials |
| NCT05945732 | DESTINY Breast Respond HER2-(Ultra)Low Europe | recruiting | — | 2,295 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer(RAMP 301) | recruiting | Phase 3 | 270 | Verastem, Inc.INDUSTRY | 16 | Aug 14, 2026 | clinicaltrials |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT(DURGA-5) | recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Aug 14, 2026 | clinicaltrials |
| NCT03911128 | A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | — | 500 | Mats HeymanOTHER | 8 | Aug 13, 2026 | clinicaltrials |
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0(BIOMEDE 2) | recruiting | Phase 3 | 433 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Aug 13, 2026 | clinicaltrials |
| NCT02290522 | Copenhagen Prospective Personalized Oncology (CoPPO)(CoPPO) | recruiting | N/A | 500 | Ulrik LassenOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02300766 | Cerebellar Mutism Syndrome Study | recruiting | — | 2,000 | Rigshospitalet, DenmarkOTHER | 14 | Aug 12, 2026 | clinicaltrials |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | Phase 3 | 6,430 | Mats HeymanOTHER | 15 | Aug 12, 2026 | clinicaltrials |
| NCT05145244 | Copenhagen Master Observational Trial(C-MOT) | recruiting | — | 2,400 | Rigshospitalet, DenmarkOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05444348 | Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)(ACT) | recruiting | N/A | 920 | Christoffer JohansenOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05707078 | PET/CT Follow up for Head and Neck Squamous Cell Carcinoma(PET Follow) | recruiting | N/A | 600 | Rigshospitalet, DenmarkOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07160725 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 540 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | recruiting | Phase 1 | 190 | Immunome, Inc.INDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT06542250 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.(TITANium) | recruiting | Phase 1 / Phase 2 | 174 | AstraZenecaINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT04077307 | A Study in Leukemia Patients With Karonudib(MAATEO) | recruiting | Phase 1 | 50 | Thomas Helleday FoundationOTHER | 3 | Aug 6, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT04746729 | Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy(HARMONIC-RT) | recruiting | — | 2,670 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 4 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT07429071 | Effectiveness of a Vaginal Gel on CIN1/2 Regression and HPV Clearance. | recruiting | N/A | 70 | University of AarhusOTHER | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials